|
Patent landscape, scope, and claims: |
Scope and claims analysis for US Patent 9,387,182 (aripiprazole or metabolites + serotonin reuptake inhibitor for depression-spectrum indications)
US 9,387,182 claims follow a tight therapeutic pairing: an aripiprazole entity (aripiprazole itself or specified aripiprazole metabolites) combined with a specified serotonin reuptake inhibitor (SSRI/SNRI-class) including citalopram/escitalopram and multiple other listed agents, optionally with specific crystalline form (anhydrous aripiprazole crystals B), pharmaceutically acceptable carriers, and broad depression- and dementia-related mood-disorder use statements. The independent claim set is composition-focused and is backed by parallel method-of-treatment claims using the same ingredient pairings. From a freedom-to-operate standpoint, the claim scope is driven less by dosing or formulation technology and more by (i) inclusion of the metabolite set (dehydroaripiprazole, DM‑1451, DM‑1452) versus aripiprazole alone and (ii) inclusion of the SSRI/SNRI list versus any other antidepressant.
What does US Patent 9,387,182 claim coverage for aripiprazole–SSRI/SNRI combinations
Answer: The patent claims compositions and treatment methods comprising (a) aripiprazole or one of three specified aripiprazole metabolites, in combination with (b) at least one serotonin reuptake inhibitor chosen from a defined list of antidepressants and their salts. Claim 5 adds a specific aripiprazole solid-state qualifier (anhydrous aripiprazole crystals B).
Composition claim scope (independent and dependent structure)
The claims you provided fall into three “ingredient-pair” families:
-
Aripiprazole or specified metabolites + SSRI/SNRI list
- Claim 1: aripiprazole or metabolite selected from dehydroaripiprazole, DM‑1451, DM‑1452 combined with an SSRI/SNRI from the specified antidepressant list (including fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts).
- Claim 10: same as claim 1 but framed as “metabolite of aripiprazole” (still the same metabolite list) + SSRI/SNRI list.
-
Aripiprazole (explicitly) + SSRI/SNRI list
- Claim 2: aripiprazole + SSRI/SNRI list (fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, salts).
- Claim 3: aripiprazole + escitalopram or a salt.
- Claim 4: claim 2 specialized to citalopram.
-
Method-of-use mirroring composition claims
- Claims 17–19: method of treating the listed mood disorders using administering a composition that matches Claims 1–3 structure (metabolite set + SSRI/SNRI; or aripiprazole + SSRI/SNRI; or aripiprazole + escitalopram).
- Claims 26–28: method using metabolite-set composition + SSRI/SNRI list (with citalopram/escitalopram dependent specializations).
- Claims 20, 21, 23–25, 27, 28, 30–32 create further alignment with citalopram/escitalopram and the mood-disorder subrange.
What is “in scope” at the ingredient level
Core in-scope ingredient pairings per claims:
This structure means a product or regimen avoids the claim only if it eliminates at least one required element:
- excludes the metabolite set and excludes aripiprazole, or
- uses a serotonin reuptake inhibitor not on the list (even if it is pharmacologically similar), or
- uses a different class antidepressant (per the claim wording, “at least one serotonin reuptake inhibitor” is limited to those enumerated).
Solid-state qualifier and carrier limitation
- Claim 5 / Claim 21: introduces anhydrous aripiprazole crystals B. This is a dependent limitation; literal infringement requires crystals B when that claim is asserted, but it also signals the patent’s position that specific aripiprazole material forms can be within scope.
- Claims 6, 13, 22, 29: add “at least one pharmaceutically acceptable carrier.” This is a standard dependent claim that typically broadens practical use of the composition claim but does not change ingredient selection.
Use-claim breadth: depression and dementia-related mood indications
- Claim 7–9 (composition claim usage): treatment of depression/major depressive disorder and a broad set of mood disorder variants.
- Claim 8: major depressive disorder or dementia with depressive symptoms.
- Claim 9: expansive list including:
- major depressive disorder, endogenous depression, melancholia
- depression with psychotic episodes
- bipolar disorder with depressive phase
- refractory depression
- dementia of Alzheimer’s type with depressive symptoms
- Parkinson’s disease with depressive symptom
- senile dementia
- mood disorder associated with cerebral blood vessels
- mood disorder following head injury
- Claims 17, 18, 19, 23–25: method claims that repeat these same condition groupings for the same ingredient pairings.
Key point for scope: the claims are not limited to a single psychiatric diagnostic label. They cover multiple depression-spectrum and dementia-associated depressive symptom use scenarios.
How broad are the “aripiprazole metabolite” claims in US 9,387,182
Answer: The patent defines metabolite coverage by an explicit three-member set (dehydroaripiprazole, DM‑1451, DM‑1452). The scope is broad in that it covers any composition where those metabolites are the aripiprazole “compound” component, but narrow because it does not include other aripiprazole metabolites unless they fall within those enumerated labels.
Claims that specifically call out metabolite coverage
- Claim 1: metabolite selected from dehydroaripiprazole, DM‑1451, DM‑1452 combined with SSRI/SNRI list.
- Claim 10: at least one metabolite selected from the same set + SSRI/SNRI list.
- Method equivalents: claims 17 and 26 (with dependent citalopram/escitalopram specializations in claims 27–28).
Practical infringement triggers tied to metabolite selection
A product is more exposed if it includes:
- aripiprazole metabolites as actives or formed constituents in a defined composition (literal “metabolite of aripiprazole” framing), or
- a regimen/technology that delivers those metabolites as such or as the intended active species.
A product is less exposed if it relies solely on:
- aripiprazole parent compound (still covered by Claims 2–4 and method claims 18–20 depending on the SSRI/SNRI used),
- but avoids the metabolite set and avoids the enumerated SSRI/SNRI list (harder to do given the list includes citalopram and escitalopram, which are common comparators).
Which serotonin reuptake inhibitors are explicitly protected by US 9,387,182
Answer: The claim language ties protection to an enumerated SSRI/SNRI list. Literal coverage exists when the SSRI/SNRI used is one of: fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts.
List by claim group (to track any internal differences)
- Claim 1 (and Claim 10): includes escitalopram in the SSRI/SNRI list.
- Claim 2: lists fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline; salts thereof.
- Claim 3: escitalopram (or salt) is explicitly isolated.
- Claim 4: citalopram isolated as dependent to Claim 2.
Scope implication: A regimen using aripiprazole + a listed serotonin reuptake inhibitor is within at least the aripiprazole composition family; a regimen using aripiprazole + escitalopram is captured directly by claim 3 and method claim 19.
When does US Patent 9,387,182 expire and when do exclusivity windows end?
Answer: Insufficient information is available in the prompt to determine priority/filing dates, statutory term, patent term adjustment, and any pediatric extension. No accurate expiration date or exclusivity end date can be produced from the claim text alone.
What patent landscape surrounds US 9,387,182 for aripiprazole + antidepressant combinations
Answer: The prompt provides claim text only. A patent landscape requires identification of: application number, inventors/assignees, continuation or divisional families, related patents, and citations/claim charts in litigation or regulatory records. Those data are not included, so no complete, accurate landscape can be constructed.
What Orange Book status applies to US 9,387,182 for combination regimens
Answer: Orange Book status requires drug-product listing data for the relevant NDA/ANDA(s), including associated patents and claim numbers tied to the listed products. The prompt includes only US Patent 9,387,182 and does not include the FDA application references, product names, or Orange Book linkages. No complete status can be produced.
How can competitors design around US 9,387,182 given its claim structure
Answer: Based strictly on claim elements shown, design-around must change at least one required claim element: the aripiprazole entity (aripiprazole vs one of three metabolites), or the serotonin reuptake inhibitor from the enumerated list.
Ingredient-pair design-around options implied by the claims
-
Switch the antidepressant away from the enumerated list
- The most straightforward avoidance is selecting a serotonin reuptake inhibitor that is not on the enumerated list.
- If the antidepressant is on the list (citalopram/escitalopram included), avoidance is unlikely on a literal-claims basis.
-
Avoid both aripiprazole and the specified metabolite set
- A product using a different antipsychotic or different aripiprazole-related active not covered by the metabolite enumeration would reduce risk, assuming no doctrine-of-equivalents coverage is asserted beyond metabolite identity.
-
Avoid the special crystalline form for dependent claims
- Claims limited to anhydrous aripiprazole crystals B (Claims 5 and 21) can be avoided by using other aripiprazole forms, but independent claims (1–4 and corresponding methods) are not limited to crystals B.
Litigation leverage created by broad versus dependent boundaries
- Independent ingredient-pair claims (1–4, 10, 17–19, 26) are broad across carriers and include broad depression-spectrum indications.
- Crystals B and carrier are dependent limitations and are secondary to ingredient matching.
Do the method-of-use claims broaden infringement risk beyond compositions
Answer: Yes. The method claims recite administering an effective amount of the claimed composition to treat a specified set of mood disorders, matching the ingredient pair logic of the composition claims.
What is required for method infringement per the claim wording
- A patient with one of the listed mood disorders, and
- administration of a composition matching one of the claim structures:
- metabolite-set + enumerated SSRI/SNRI, or
- aripiprazole + enumerated SSRI/SNRI (including escitalopram), or
- aripiprazole + citalopram (dependent).
This can matter for combination regimens where products are marketed separately but used together in a way that maps to the method claim wording (fact patterns depend on jurisdiction and enforcement theory).
Key Takeaways
- Claim scope is ingredient-driven. Coverage turns on (i) aripiprazole vs one of three specified aripiprazole metabolites (dehydroaripiprazole, DM‑1451, DM‑1452) and (ii) co-administration with one of nine enumerated serotonin reuptake inhibitors (including citalopram and escitalopram) and salts.
- Depression and dementia-related mood disorder indications are broad. The claims list depression-spectrum disorders and depressive symptoms in dementia (including Alzheimer’s-type and Parkinson’s-linked cases) plus several other mood disorder variants.
- Dependent claims add technical constraints, not the core exposure. Crystals B and pharmaceutically acceptable carriers are dependent; they are less important than matching the aripiprazole/metabolite plus SSRI/SNRI pair.
- A complete expiration date, Orange Book status, and surrounding patent landscape cannot be computed from the claim text alone.
FAQs
-
Does US 9,387,182 require a specific dose or dosing schedule for infringement?
The claim text provided uses “effective amount” without dose ranges or schedules, so dose specificity is not present in the claim elements shown.
-
Are antidepressants outside the enumerated list covered if they are serotonin reuptake inhibitors?
The claims define the serotonin reuptake inhibitors by an explicit list; coverage depends on the selected agent falling within that list.
-
Is escitalopram covered only under a dedicated claim or also within broader claims?
Escitalopram appears in the broader SSRI/SNRI lists (claim 1 family) and is also isolated in claim 3 and method claim 19.
-
Does using “anhydrous aripiprazole crystals B” change exposure for independent claims?
Crystals B is in dependent claims (5 and 21). Independent claims are not limited to crystals B.
-
Can the metabolite claims be avoided by using only parent aripiprazole?
Parent-only regimens are still covered by aripiprazole composition claims (2–4) and the corresponding method claims if the co-administered SSRI/SNRI is from the enumerated list.
References
- US Patent 9,387,182 (claim text provided in prompt).
More… ↓
⤷ Start Trial
|
